Treatment Patterns And Survival Outcomes Of Nsclc Patients Initially

| Treatment Patterns And Survival Outcomes Of NSCLC Patients Initially ...

| Treatment Patterns And Survival Outcomes Of NSCLC Patients Initially ... Advanced NSCLC treatment lacks standardized next-line therapies, with significant variability in clinical practice observed Median progression-free survival was 529 months, and overall survival was A total of 1,011 patients met the inclusion criteria Most were male (571%), married (541%), and had no comorbidities (558%) A significant proportion of patients (711%) were diagnosed at stages

Initial Treatment And Survival Outcomes In Patients With Stage III ...

Initial Treatment And Survival Outcomes In Patients With Stage III ... Implementation of Real-World Diagnostic Strategies in Taiwan for the Identification of Targetable Oncogenic Driver Alterations in Non–Small Cell Lung Cancer We conducted a multicenter retrospective Consolidation durvalumab is underutilized in unresectable stage III NSCLC, with only 615% of eligible patients receiving it post-cCRT Patients receiving durvalumab after cCRT show improved survival A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer (NSCLC) BioAtla, Inc reported promising results for its treatment, Mecbotamab Vedotin (Mec-V), in patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) At the

Overall Survival For All Patients With Stage I NSCLC By Treatment ...

Overall Survival For All Patients With Stage I NSCLC By Treatment ... A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer (NSCLC) BioAtla, Inc reported promising results for its treatment, Mecbotamab Vedotin (Mec-V), in patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) At the Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points Among patients with oncogene-driven advanced non–small A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients

Real-World Treatment Patterns of Alectinib in Unselected Spanish ALK+ NSCLC Patients | Oncotarget